Author:
Lesko Lawrence J.,Woodcock Janet
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Reference11 articles.
1. DiMasi, J., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).
2. Gilbert, J. Rebuilding big PhRMA's business model. In Vivo November, 73–80 (2003).
3. Tufts CDSS quantifies savings from boosting new drug R&D efficiency. Tufts CSDD Impact Report 4, 1–4 (2002).
4. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Eng. J. Med. 350, 2129–2139 (2004).
5. Guillermo Paez, J. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib. Science 304, 1497–1500 (2004).
Cited by
178 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献